<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03766997</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-breast-IGM</org_study_id>
    <nct_id>NCT03766997</nct_id>
  </id_info>
  <brief_title>Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)</brief_title>
  <acronym>LSTIGM</acronym>
  <official_title>A Randomized Controlled Study on the Effectiveness of Local Injection Combined With Topical Steroids vs. Topical Steroids Mono-therapy in the Treatment of Idiopathic Granulomatous Mastitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical response rate of local steroids in the treatment of
      idiopathic granulomatous mastitis in female adults. Half of the participants will receive
      local injection combined with topical steroids and the other half will receive topical
      steroids mono-therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory breast disease of
      unknown etiology.Clinical presentation of IGM can be variable. Some findings may be confused
      with breast malignancy.

      Although IGM as a disease has been known for nearly four decades, no treatment consensus has
      been reached because of its rarity. Surgical treatment, antibiotics, oral steroids, topical
      steroids, immunosuppression (methotrexate, mycophenolate mofetil) and close follow up have
      all been reported to be effective.

      Currently,surgical treatment and systemic steroids treatment are most frequently employed.
      With the consideration of side effects of long term systemic (oral) steroid usage, topical
      steroids without systemic use were assessed and showed satisfactory curative effect. But
      there is no data concerning the use of local injection of steroids therapy on IGM.The purpose
      of this study is to evaluate the effectiveness of steroids local injection on the basis of
      topical steroids for IGM treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>six months</time_frame>
    <description>The clinical response is categorized into ''completely healed,'' ''inadequately healed,'' ''stable,'' ''worsened,'' or ''relapsed'' if the lesions had once healed but symptoms returned.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>granulomatous mastitis recurrence</measure>
    <time_frame>two years</time_frame>
    <description>IGM relapses in the Ipsilateral breast.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Granulomatous Mastitis</condition>
  <arm_group>
    <arm_group_label>local injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound betamethasone injection (Each injection contains betamethasone dipropionate at 5 mg for betamethasone and betamethasone sodium phosphate at 2 mg for betamethasone) was local injected to the breast by the patient once a week for one to four times followed by Hydrocortisone butyrate cream(0.1%) topical use twice a day until the termination of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>topical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocortisone butyrate 0.1% cream was applied to the breast by the patient twice a day until the termination of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Betamethasone Injection</intervention_name>
    <description>local injection</description>
    <arm_group_label>local injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone Butyrate 0.1% Cream</intervention_name>
    <description>topical use</description>
    <arm_group_label>local injection</arm_group_label>
    <arm_group_label>topical</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Granulomatous Mastitis

          -  Require non-surgical treatment

        Exclusion Criteria:

          -  Breast Carcinoma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Sun, Master</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanna Zhang, M.D.</last_name>
    <phone>86-10-69158703</phone>
    <email>pumchzyn@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Breast Surgery,Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Sun, Master</last_name>
      <phone>86-010-69158720</phone>
      <email>sunqiangpumc@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanna Zhang, Doctor</last_name>
      <phone>86-010-69158703</phone>
      <email>pumchzyn@sohu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yanna Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tahmasebi S, Karami MY, Maalhagh M. Granulomatous Mastitis: Time to Introduce New Weapons. World J Surg. 2016 Nov;40(11):2827-2828.</citation>
    <PMID>26920409</PMID>
  </reference>
  <reference>
    <citation>Altintoprak F, Kivilcim T, Yalkin O, Uzunoglu Y, Kahyaoglu Z, Dilek ON. Topical Steroids Are Effective in the Treatment of Idiopathic Granulomatous Mastitis. World J Surg. 2015 Nov;39(11):2718-23. doi: 10.1007/s00268-015-3147-9.</citation>
    <PMID>26148520</PMID>
  </reference>
  <reference>
    <citation>Sheybani F, Naderi HR, Gharib M, Sarvghad M, Mirfeizi Z. Idiopathic granulomatous mastitis: Long-discussed but yet-to-be-known. Autoimmunity. 2016 Jun;49(4):236-9. doi: 10.3109/08916934.2016.1138221. Epub 2016 Feb 1. Review.</citation>
    <PMID>26829298</PMID>
  </reference>
  <reference>
    <citation>Benson JR, Dumitru D. Idiopathic granulomatous mastitis: presentation, investigation and management. Future Oncol. 2016 Jun;12(11):1381-94. doi: 10.2217/fon-2015-0038. Epub 2016 Apr 12. Review.</citation>
    <PMID>27067146</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulomatous Mastitis</keyword>
  <keyword>local injection</keyword>
  <keyword>topical steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastitis</mesh_term>
    <mesh_term>Granulomatous Mastitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Hydrocortisone-17-butyrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

